Navigation Links
Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients

A recent three-way crossover study over six weeks by clinicians at the National Heart and Lung Institute, Royal Brompton Hospital, London has shown that Salmeterol produced a novel anti-neutrophilic effect among patients with mild asthma. The study was prompted by the long standing argument about the effects of long-acting beta2-adrenergic receptor agonists, such as salmeterol, on inflammation. The clinicians enrolled 20 patients, between the ages// of 18 and 55, with mild stable asthma who were randomized to receive salmeterol (50 micrograms b.d), fluticasone propionate (250 micrograms b.d), or placebo. They investigated the effect of salmeterol on the numbers of inflammatory cells in biopsy samples of distinct immuno-phenotype and those expressing the genes for interleukin-4 and -5, regulatory cytokines which are particularly relevant to asthma.

The numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble E-selectin in serum, each of which reflect neutrophil involvement, was found to be significantly reduced in subjects who were given salmeterol compared to those who were given the placebo. Salmeterol, compared with fluticasone propionate, reduced neutrophil number and human neutrophil lipocalin level in bronchial lavage fluid, and intercellular adhesion molecule-1 level in bronchoalveolar lavage fluid. It was also observed that the numbers of (CD3+) T-lymphocytes, (CD4+) T-helper cells, (CD45RO+) activated T-helper cells and eosinophils in the biopsy samples were significantly reduced with fluticasone propionate, compared with placebo. Fluticasone propionate also reduced the percentage of eosinophils and soluble intercellular adhesion molecule-1 in serum.

The clinicians also found that after the use of salmeterol, as compared with both fluticasone propionate and placebo, the airways hyper-responsiveness and the percentage of symptom-free days and nights improved significantly.


'"/>




Page: 1

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Therapy for Chronic Problem
8. Blood Sugar Kept In Control By Novel Protein
9. Novel antibiotic dressing developed for improved wound healing
10. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
11. Novel drug holds promise for treatment of Rheumatoid Arthritis
Post Your Comments:
(Date:10/7/2008)... WASHINGTON, Oct. 7 /PRNewswire-USNewswire/ -- ...ecent winner of Dancing With the Stars, has been,n...ation Christmas Seals,Campaign in an effort to hel...sion: to prevent lung disease and promote lung hea...ls tradition began in 1907,to conquer Tuberculosis...
(Date:10/7/2008)...Less likely to feel distress, more likely to enjoy... TUESDAY, Oct. 7 (HealthDay News) -- End-of-life d...atient do not result in more distress for patients...interventions and enhanced quality of life in a pa... "For the past two decades, the debate has been ar...
(Date:10/7/2008)..., Surprise announcement of planned bequest comes .../PRNewswire-USNewswire/ -- Just over one year,ago,...million gift to the,University of Michigan, to end..., treating and preventing human disease., Today, ...n --,announcing that he will bequeath an additiona...
(Date:10/7/2008)...These brain-damaged individuals show signs of awar...AY, Oct. 7 (HealthDay News) -- Severely brain-dam... still feel pain and require painkilling treatment...ally conscious state (MCS) is different than a per...efulness without awareness of self or surroundings...
Breaking Medicine News(10 mins):Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Patients Benefit From End-of-Life Discussions With a Doctor 2Health News:Patients Benefit From End-of-Life Discussions With a Doctor 3Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Patients in Minimally Conscious State May Still Feel Pain 2
...bout one in three children in California is overwe...to statistics released by a health insurance compa... the Los Angeles County, which comprises 88 satell... overweight children in the county is about three ...
...close schools for up to three months in the event ...ould be canceled and working hours //staggered so ...vernment advised today in issuing new pandemic flu...h officials acknowledged that such measures would ...
On the 'Fast Buck' Trail: Kidneys on Sale
...ned from animals that are cloned will not bear any...s safe for consumption, there is no necessary to i... Press, the approval from the U.S. Government on c...s expected within a year. The Food and Drug Admini...
Other Medicine News:Health News:U.S. Issues Guidelines in Case of Flu Pandemic 2Health News:U.S. Issues Guidelines in Case of Flu Pandemic 3Health News:U.S. Issues Guidelines in Case of Flu Pandemic 4Health News:On the 'Fast Buck' Trail: Kidneys on Sale 2Health News:On the 'Fast Buck' Trail: Kidneys on Sale 3Health News:On the 'Fast Buck' Trail: Kidneys on Sale 4Health News:On the 'Fast Buck' Trail: Kidneys on Sale 5Health News:On the 'Fast Buck' Trail: Kidneys on Sale 6Health News:On the 'Fast Buck' Trail: Kidneys on Sale 7
(Date:10/7/2008)...tCall/ -- CEL-SCI Corporation,(NYSE: CVM ) announ...sfer,Agreement (MTA) with the National Institutes ...ry of Dr. Francesco M. Marincola, M.D., to,investi...icroenvironment,caused by CEL-SCI,s cancer drug Mu...ous Disease and Immunogentics Section, Department ...
(Date:10/7/2008).../ -- Aerovance Inc. today reported,pharmacokinetic...Aerovant,inhalation powder that demonstrate good t...llowing asthma patients, inhalation of a single 10... three doses investigated in,Aerovance,s Phase IIb...arly,next year. Evidence gathered from nonclinical...
(Date:10/7/2008)... Tests for Use on the GeneXpert(R) ...7 /- Cepheid (Nasdaq:,CPHD)...B as a European CE,IVD Mark product under the Euro...ces. The test delivers rapid detection of vanA and... with vancomycin-resistant,enterococci (VRE) -- on...
(Date:10/6/2008)...e/ -- "A return to the use of,chimpanzees in AIDS ...ific,justification," according to a paper released...nimals (ATLA). "An Assessment of the Role of,Chimp...ccine responses in,chimpanzees are not predictive ...zees, critical role and importance in AIDS vaccine...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Salugen to Present at Nutrition Capital Networks First In Person Investor Meeting 1154 1Salugen to Present at Nutrition Capital Networks First In Person Investor Meeting 1154 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 1152 1University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 1152 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 1152 3Prostate cancer more likely to return in blacks than whites but the disease is not more aggressive 3212 1Prostate cancer more likely to return in blacks than whites but the disease is not more aggressive 3212 2Fruit and vegetables health 3210 1
...fety of Gene Therapy in Lipoprotein Lipase,Deficie... 31, 2007 - Amsterdam Molecular,Therapeutics (AMT)...orted positive Phase I/II clinical trial results w...MT-011) in Complete,Lipoprotein Lipase (LPL) defic...erican Society of Gene Therapy (ASGT) in Seattle.,...
...rom XL880, Phase II data from XL999 studies,schedu...-, SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-F...ata from clinical trials of,the company,s investig...d at the 2007 American Society of Clinical Oncolog...1 to 5 in Chicago,Illinois. , , -- Data from t...
Other Medicine Technology:AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy 2AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy 3AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy 4Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2
...ontinuous low-flow nebulizer performance. Patented...allows for optimal medication and Heliox delivery ...vere asthma, COPD and pneumonia in both routine an... mouth and T-piece to deliver high-output, low-flo...
... diverse medical products for more than 58 years. ...anding reputation for innovation, quality and cust...ecognized brands include the Labtron® line of ... products, Bristoline® microscopes, HealthTeam...
...contains everything the health care professional n...ickly and efficiently: 7 nebulizers, T-piece and m...yringe and needle., ,Shipped 5 kits per case., ,...ed Use: AsthmaKit is a procedural kit providing th...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
Medicine Products: